Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (ThRiL) as Initial Treatment for Patients With CLL
Status:
Completed
Trial end date:
2020-12-29
Target enrollment:
Participant gender:
Summary
The investigators' hypothesis is that treatment of CLL with an alternating daily dosing
schedule of thalidomide and lenalidomide may result in better tolerability by decreasing each
agent's individual toxicities, while preserving efficacy, and therefore lead to a longer
duration of therapy and improved responses. Additionally, the combination of the 2 agents may
have additive or synergistic effects therapeutically.
In Cycle -1, odd numbered patients will receive oral thalidomide daily days 1-14 followed by
no treatment on days 15-28. Even numbered patients will receive oral lenalidomide daily on
days 1-14 and then no treatment on days 15-28. Starting with cycle 1, patients will alternate
daily thalidomide (every odd day) with daily lenalidomide (every even day) for days 1-28.
Rituximab will be given on days 1, 8, 15, and 22 starting with Cycle 1, and then again every
6th cycle thereafter (cycles 7, 13, 19, etc.)